PMID- 14633873
OWN - NLM
STAT- MEDLINE
DCOM- 20031219
LR  - 20190722
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 49
IP  - 12
DP  - 2003 Dec
TI  - Prognostic value of combination of cardiac troponin T and B-type natriuretic 
      peptide after initiation of treatment in patients with chronic heart failure.
PG  - 2020-6
AB  - BACKGROUND: Recent studies have suggested that cardiac troponin T (cTnT) and 
      troponin I may detect ongoing myocardial damage involved in the progression of 
      chronic heart failure (CHF). This study was prospectively designed to examine 
      whether the combination of cTnT, a marker for ongoing myocardial damage, and 
      B-type natriuretic peptide (BNP), a marker for left ventricular overload, would 
      effectively stratify patients with CHF after initiation of treatment. METHODS: We 
      measured serum cTnT, plasma BNP, and left ventricular ejection fraction (LVEF) on 
      admission for worsening CHF [New York Heart Association (NYHA) functional class 
      III to IV] and 2 months after initiation of treatment to stabilize CHF (n = 100; 
      mean age, 68 years). RESULTS: Mean (SD) concentrations of cTnT [0.023 (0.066) vs 
      0.063 (0.20) micro g/L] and BNP [249 (276) vs 753 (598) ng/L], percentage 
      increased cTnT (>0.01 micro g/L; 35% vs 60%), NYHA functional class [2.5 (0.6) vs 
      3.5 (5)], and LVEF [43 (13)% vs 36 (12)%] were significantly (P <0.01) improved 2 
      months after treatment compared with admission. During a mean follow-up of 391 
      days, there were 44 cardiac events, including 12 cardiac deaths and 32 
      readmissions for worsening CHF. On a stepwise Cox regression analysis, increased 
      cTnT and BNP were independent predictors of cardiac events (P <0.001). cTnT >0.01 
      micro g/L and/or BNP >160 ng/L 2 months after initiation of treatment were 
      associated with increased cardiac mortality and morbidity rates. CONCLUSION: The 
      combination of cTnT and BNP measurements after initiation of treatment may be 
      highly effective for risk stratification in patients with CHF.
FAU - Ishii, Junnichi
AU  - Ishii J
AD  - Division of Critical Care, Fujita Health University Graduate School of Health 
      Sciences, Toyoake 470-1192, Japan. jishi@fujita-hu.ac.jp
FAU - Cui, Wei
AU  - Cui W
FAU - Kitagawa, Fumihiko
AU  - Kitagawa F
FAU - Kuno, Takahiro
AU  - Kuno T
FAU - Nakamura, Yuu
AU  - Nakamura Y
FAU - Naruse, Hiroyuki
AU  - Naruse H
FAU - Mori, Yoshihisa
AU  - Mori Y
FAU - Ishikawa, Takashi
AU  - Ishikawa T
FAU - Nagamura, Youichi
AU  - Nagamura Y
FAU - Kondo, Takeshi
AU  - Kondo T
FAU - Oshima, Hisaji
AU  - Oshima H
FAU - Nomura, Masanori
AU  - Nomura M
FAU - Ezaki, Kouji
AU  - Ezaki K
FAU - Hishida, Hitoshi
AU  - Hishida H
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Biomarkers)
RN  - 0 (Troponin T)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Chronic Disease
MH  - Female
MH  - Heart Failure/*diagnosis/drug therapy/mortality
MH  - Humans
MH  - Male
MH  - Natriuretic Peptide, Brain/*blood
MH  - Patient Readmission/statistics & numerical data
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Troponin T/*blood
MH  - Ventricular Function, Left
EDAT- 2003/11/25 05:00
MHDA- 2003/12/20 05:00
CRDT- 2003/11/25 05:00
PHST- 2003/11/25 05:00 [pubmed]
PHST- 2003/12/20 05:00 [medline]
PHST- 2003/11/25 05:00 [entrez]
AID - 49/12/2020 [pii]
AID - 10.1373/clinchem.2003.021311 [doi]
PST - ppublish
SO  - Clin Chem. 2003 Dec;49(12):2020-6. doi: 10.1373/clinchem.2003.021311.